NASDAQ:QNRX

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals announced it achieved 4% rapamycin in a topical lotion and 5% in a dermal patch, clearing a key formulation barrier for human trials. QNRX shares surged, with pre-market gains near 66%. Clinical and stability batch manufacturing is set for late 2025, with first-in-human studies planned for early 2026 targeting microcystic lymphatic and venous malformations.

11 November 2025

Biotechnology·Healthcare News·NASDAQ:QNRX·Pharmaceuticals

Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

Quoin Pharmaceuticals shares surged over 150% on Oct. 10, closing at $20.50 after announcing a $104.5 million private placement with institutional healthcare investors. Intraday, the stock touched $41.80 before retreating. Market cap rose to about $160–170 million. The company, which has no products on the market, is developing QRX003 for Netherton Syndrome and recently secured FDA and EMA orphan drug designations.

11 October 2025

NASDAQ:QNRX·Stock Market

U.S. Natural Gas Prices Drop on Warmer Weather, Supply Factors Sustain Pressure
March 20, 2026, 5:19 PM EDT. Natural gas prices for April Nymex delivery fell 2.24% as US weather forecasts turned warmer, potentially lowering heating demand. The Commodity Weather Group predicts above-average temperatures in the western US through March 29, pressuring prices. However, a recent Iranian attack on Qatar's Ras Laffan LNG export facility, which supplies 20% of global liquefied natural gas, could limit further declines. US dry gas production rose 4.8% year-on-year, nearing record highs with rigs increasing to a 2.5-year peak. Inventories surged by 35 billion cubic feet last week, well above average, indicating ample supply. Despite these bearish signals, rising electricity output and export potential from Qatar's damaged plant could support prices amid global supply disruptions.